zoledronic acid has been researched along with Urinary Bladder Neoplasms in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 8 (66.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Baker, AT; Davey, MS; Le Duff, CS; Malde, R; Mehellou, Y; Mykura, RC; Taher, TE; Willcox, BE | 1 |
| Benmerzoug, S; Cesson, V; Chevalier, MF; Dartiguenave, F; Derré, L; Jichlinski, P; Lucca, I; Nardelli-Haefliger, D; Nguyen, S; Rodrigues-Dias, SC; Roth, B; Schneider, AK | 1 |
| Alcaraz, A; Alvarez-Ossorio, JL; Bellmunt, J; Calderero, V; Carles, J; Chirivella, I; Climent, M; Comet-Batlle, J; Contreras, JA; de la Piedra, C; Esteban, E; González-Del Alba, A; González-Enguita, C; González-Gragera, B; González-López, R; Lara, PC; Lassa, A; León-Mateos, L; Mahillo-Fernández, I; Mañas, A; Mellado, B; Méndez, MJ; Meseguer, C; Morote, J; Murias, A; Samper, P; Segarra, J; Unda, M; Vázquez, F | 1 |
| Froehner, M; Hakenberg, OW; Hölscher, T; Wirth, MP | 1 |
| Ashihara, E; Habuchi, T; Kimura, S; Maekawa, T; Maita, S; Sato, K; Takeuchi, M; Tsuchiya, N; Yuasa, T | 1 |
| Berruti, A; Brizzi, MP; Dogliotti, L; Gorzegno, G; Porpiglia, F; Priola, AM; Ragni, F; Sculli, CM; Tampellini, M | 1 |
| Boutrus, R; El-Attar, I; El-Hossieny, H; Kader, YA; Nazmy, M; Zaghloul, MS | 1 |
| Fujikawa, Y; Kadoya, S; Matsumoto, Y; Murakami, N; Murasugi, K; Ohura, F; Tanabe, K; Yoshii, I | 1 |
| Eastham, JA; Saad, F | 1 |
| Aksoy, S; Arık, Z; Ozdemir, NY; Sendur, MA; Uncu, D; Yaman, S; Zengin, N | 1 |
| Armstrong, AJ; Fizazi, K; Freedland, S; Pienta, K; Saad, F; Saylor, PJ; Smith, MR; Tombal, B | 1 |
| Kenna, T; Mattarollo, SR; Nicol, AJ; Nieda, M | 1 |
3 review(s) available for zoledronic acid and Urinary Bladder Neoplasms
| Article | Year |
|---|---|
Treatment of bone metastases in urologic malignancies.
Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Cisplatin; Denosumab; Diphosphonates; Humans; Imidazoles; Male; Neoplasm Metastasis; Neoplasms, Germ Cell and Embryonal; Prostatic Neoplasms; Quality of Life; Radiosurgery; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms; Zoledronic Acid | 2014 |
Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Disease Progression; Humans; Imidazoles; Kidney Neoplasms; Survival Analysis; Urinary Bladder Neoplasms; Zoledronic Acid | 2010 |
New and emerging therapies for bone metastases in genitourinary cancers.
Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Kidney Neoplasms; Male; Prospective Studies; Prostatic Neoplasms; Radiopharmaceuticals; Radium; Randomized Controlled Trials as Topic; RANK Ligand; Urinary Bladder Neoplasms; Urogenital Neoplasms; Urothelium; Zoledronic Acid | 2013 |
1 trial(s) available for zoledronic acid and Urinary Bladder Neoplasms
| Article | Year |
|---|---|
A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer.
Topics: Adult; Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Drug Administration Schedule; Egypt; Female; Fractures, Bone; Humans; Hypercalcemia; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Pain; Placebo Effect; Prospective Studies; Risk Assessment; Risk Factors; Spinal Cord Compression; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Zoledronic Acid | 2010 |
8 other study(ies) available for zoledronic acid and Urinary Bladder Neoplasms
| Article | Year |
|---|---|
Synthesis and Biological Evaluation of ( E)-4-Hydroxy-3-methylbut-2-enyl Phosphate (HMBP) Aryloxy Triester Phosphoramidate Prodrugs as Activators of Vγ9/Vδ2 T-Cell Immune Responses.
Topics: Amides; Cells, Cultured; Humans; Immunotherapy; Lymphocyte Activation; Organophosphates; Phosphoric Acids; Prodrugs; Receptors, Antigen, T-Cell, gamma-delta; T-Cell Antigen Receptor Specificity; T-Lymphocyte Subsets; Urinary Bladder Neoplasms | 2018 |
Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments.
Topics: Animals; BCG Vaccine; Humans; Mice; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets; Tumor Microenvironment; Urinary Bladder Neoplasms; Zoledronic Acid | 2022 |
Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers, Tumor; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Carcinoma, Renal Cell; Collagen Type I; Diphosphonates; Disease Progression; Female; Humans; Imidazoles; Kidney Neoplasms; Male; Middle Aged; Peptide Fragments; Procollagen; Prospective Studies; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms; Zoledronic Acid | 2013 |
Intravesical administration of gammadelta T cells successfully prevents the growth of bladder cancer in the murine model.
Topics: Administration, Intravesical; Aged; Animals; Blotting, Western; Diphosphonates; Female; Histocompatibility Antigens Class I; Humans; Imidazoles; Immunohistochemistry; Immunologic Factors; Immunotherapy, Adoptive; Kaplan-Meier Estimate; Male; Mice; Mice, Inbred BALB C; Prognosis; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets; T-Lymphocytes; Urinary Bladder Neoplasms; Zoledronic Acid | 2009 |
Activity and safety of a prolonged daily schedule of zoledronic acid in a patient with bone metastases from urothelial carcinoma.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma; Diphosphonates; Drug Administration Schedule; Fatal Outcome; Female; Humans; Imidazoles; Radiography; Urinary Bladder Neoplasms; Zoledronic Acid | 2009 |
[A case report of a patient treatable by home palliative care, administered zoledronic acid used for bladder cancer with hypercalcemia].
Topics: Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Fatal Outcome; Female; Home Care Services; Humans; Hypercalcemia; Imidazoles; Palliative Care; Terminal Care; Urinary Bladder Neoplasms; Zoledronic Acid | 2010 |
Small cell carcinoma of the urinary bladder with hypercalcemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Carcinoma, Small Cell; Diphosphonates; Female; Humans; Hypercalcemia; Imidazoles; Middle Aged; Treatment Outcome; Urinary Bladder Neoplasms; Zoledronic Acid | 2012 |
Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Burkitt Lymphoma; Carcinoma; Cell Line, Tumor; Cisplatin; Colorectal Neoplasms; Concanavalin A; Cytotoxicity, Immunologic; Diphosphonates; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Genes, T-Cell Receptor delta; Genes, T-Cell Receptor gamma; Humans; Imidazoles; Interferon-gamma; Lovastatin; Lung Neoplasms; Male; Membrane Glycoproteins; Neoplasms; Perforin; Pore Forming Cytotoxic Proteins; Prostatic Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets; Urinary Bladder Neoplasms; Vincristine; Zoledronic Acid | 2007 |